Recursion RXRX Form 4: 17,584 shares withheld for taxes D&O

Recursion Pharmaceuticals, Inc. (RXRX) reported an insider equity transaction by a director and officer (Chief R&D Commercial Officer) on 11/17/2025.

Accepted by SEC EDGAR 11/19/2025 - 07:37 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Recursion Pharmaceuticals, Inc. (RXRX) reported an insider equity transaction by a director and officer (Chief R&D Commercial Officer) on 11/17/2025. The filing shows that 17,584 shares of Class A common stock were disposed of at $4.14 per share under transaction code "F," which indicates shares were withheld by the company to cover tax obligations on the net settlement of restricted stock units.

After this tax withholding event, the reporting person directly beneficially owns 735,538 shares of Class A common stock. The transaction reflects administrative share withholding for taxes rather than an open-market sale.

Insider Trade Summary

Exercise Price or Tax Liability: 17,584 shares

Exercise Price or Tax Liability 1 txn

Insider Khan Najat

Role Chief R&D Commercial Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Class A Common Stock	17,584	$4.14	$73K

Holdings After Transaction: Class A Common Stock — 735,538 shares (Direct)

Footnotes (1)

1. F1. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RXRX report in this Form 4?

The Form 4 reports that a director and Chief R&D Commercial Officer of Recursion Pharmaceuticals, Inc. (RXRX) had 17,584 shares of Class A common stock withheld to satisfy tax obligations related to restricted stock units on 11/17/2025.

Was the RXRX insider transaction an open-market sale?

No. The filing explains that the 17,584 shares were withheld by the issuer to satisfy tax withholding and remittance obligations tied to the net settlement of restricted stock units, rather than sold in the open market.

How many RXRX shares does the reporting person own after the transaction?

Following the reported transaction, the insider directly beneficially owns 735,538 shares of Recursion Pharmaceuticals Class A common stock.

What does transaction code "F" mean in this RXRX Form 4?

Transaction code "F" indicates that the shares were disposed of by the issuer to pay the insider’s tax withholding obligations in connection with an equity award, here involving restricted stock units.

What is the role of the reporting person at Recursion Pharmaceuticals (RXRX)?

The reporting person is both a director and an officer, serving as the company’s Chief R&D Commercial Officer at Recursion Pharmaceuticals, Inc.

At what price were the RXRX shares withheld for tax purposes?

The 17,584 shares of RXRX Class A common stock withheld for taxes are reported at a price of $4.14 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Khan Najat

(Last) (First) (Middle)

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UT 84101

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief R&D Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	11/17/2025		F(1)		17,584	D	$4.14	735,538	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.

Remarks:

	/s/ Kyle Nelson, attorney-in-fact	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.